U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.34 HKD 5.11% Market Closed
Market Cap: 22.4B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note

United Laboratories International Holdings Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Laboratories International Holdings Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
U
United Laboratories International Holdings Ltd
HKEX:3933
Free Cash Flow
ÂĄ1.3B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
7%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Free Cash Flow
HK$1.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
10%
Sino Biopharmaceutical Ltd
HKEX:1177
Free Cash Flow
ÂĄ5B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
10%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Free Cash Flow
ÂĄ1.9B
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
65%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Free Cash Flow
HK$15.2B
CAGR 3-Years
50%
CAGR 5-Years
19%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Free Cash Flow
-$65.3m
CAGR 3-Years
20%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.4B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.1 HKD
Undervaluation 42%
Intrinsic Value
Price
U

See Also

What is United Laboratories International Holdings Ltd's Free Cash Flow?
Free Cash Flow
1.3B CNY

Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's Free Cash Flow amounts to 1.3B CNY.

What is United Laboratories International Holdings Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
7%

Over the last year, the Free Cash Flow growth was -18%. The average annual Free Cash Flow growth rates for United Laboratories International Holdings Ltd have been 8% over the past three years , 9% over the past five years , and 7% over the past ten years .

Back to Top